- Home
- HHS vs PFSA Comparison
HHS vs PFSA Comparison
Compare HHS & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- PFSA
- Stock Information
- Founded
- HHS 1923
- PFSA 2009
- Country
- HHS United States
- PFSA United States
- Employees
- HHS N/A
- PFSA N/A
- Industry
- HHS Advertising
- PFSA Medical/Dental Instruments
- Sector
- HHS Consumer Discretionary
- PFSA Health Care
- Exchange
- HHS Nasdaq
- PFSA Nasdaq
- Market Cap
- HHS 27.3M
- PFSA 25.1M
- IPO Year
- HHS N/A
- PFSA N/A
- Fundamental
- Price
- HHS $3.69
- PFSA $0.34
- Analyst Decision
- HHS
- PFSA
- Analyst Count
- HHS 0
- PFSA 0
- Target Price
- HHS N/A
- PFSA N/A
- AVG Volume (30 Days)
- HHS 20.9K
- PFSA 21.2M
- Earning Date
- HHS 11-13-2025
- PFSA 08-14-2025
- Dividend Yield
- HHS N/A
- PFSA N/A
- EPS Growth
- HHS N/A
- PFSA N/A
- EPS
- HHS N/A
- PFSA N/A
- Revenue
- HHS $174,951,000.00
- PFSA $75,000.00
- Revenue This Year
- HHS $6.54
- PFSA N/A
- Revenue Next Year
- HHS N/A
- PFSA N/A
- P/E Ratio
- HHS N/A
- PFSA N/A
- Revenue Growth
- HHS N/A
- PFSA 66.67
- 52 Week Low
- HHS $3.06
- PFSA $0.27
- 52 Week High
- HHS $7.72
- PFSA $5.50
- Technical
- Relative Strength Index (RSI)
- HHS 51.90
- PFSA N/A
- Support Level
- HHS $3.67
- PFSA N/A
- Resistance Level
- HHS $3.83
- PFSA N/A
- Average True Range (ATR)
- HHS 0.10
- PFSA 0.00
- MACD
- HHS 0.01
- PFSA 0.00
- Stochastic Oscillator
- HHS 60.81
- PFSA 0.00
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About PFSA Profusa Inc. Common Stock
Profusa Inc is a digital health technology company based in Emeryville, CA, that has developed a real-time, consumer-friendly platform that is designed to measure an individual's biochemistry, be easy to use, be cost-effective, and provide the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.